These drug combinations showed synergistic inhibitory effects on the proliferation of HNSCC cells, suggesting that combinations of CDK and EGFR inhibitors may be particularly useful in EGFR and phosphorylated Rb-expressing or cyclin D1/CDK6-overexpressing HPV-negative HNSCC. Here, CDK6 is linked to head and neck squamous cell carcinoma.